We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · June 05, 2021

Correlating Standardized Uptake Value With pCR to Pertuzumab and Trastuzumab in Breast Cancer

Journal of Clinical Oncology


Additional Info

Journal of Clinical Oncology
Updated Results of TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathological Complete Response to Pertuzumab and Trastuzumab in Breast Cancer
J. Clin. Oncol 2021 May 17;[EPub Ahead of Print], RM Connolly, JP Leal, L Solnes, CY Huang, A Carpenter, K Gaffney, V Abramson, LA Carey, MC Liu, M Rimawi, J Specht, AM Storniolo, V Valero, C Vaklavas, IE Krop, EP Winer, M Camp, RS Miller, AC Wolff, A Cimino-Mathews, BH Park, RL Wahl, V Stearns

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading